InterMune Wagers On Pirfenidone With Sale Of Full Danoprevir Rights To Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets $175 million for HCV protease inhibitor for which some analysts had prescribed no net present value.